Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FluGen Inc.

Latest From FluGen Inc.

Pipeline Watch: Phase III Progress With Burosumab, Duvelisib And Galcanezumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Execs On The Move, October 2015

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

BioPharmaceutical Medical Device

Venture Funding Deals, October 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced August through September 2015.

BioPharmaceutical Medical Device

Arecor Ltd.

Arecor Ltd.'s Arestat technology is designed to improve the stability of biologics that otherwise can't be formulated as a liquid, because they are too unstable or the required protein concentration means that the viscosity is too high. Arecor's platform allows its collaborators to develop new products, cut their development and manufacturing costs, or gain a competitive advantage by creating a ready-to-use formulation that can be given as a smaller or faster-acting dose.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • FluGen Inc.
  • Senior Management
  • Paul V Radspinner, Pres. & CEO
    Pamuk Bilsel, PhD, VP, R&D
  • Contact Info
  • FluGen Inc.
    Phone: (608) 441-2729
    597 Science Dr.
    Madison, WI 53711